Intérêt de la tomographie à émission de positons au 18fluoro-déoxy-glucose dans la définition des champs de radiothérapie : exemple de la radiothérapie thoracique

Bendriem, 1998, Les détecteurs de positons. Caméra PET. Caméra PET-SPECT, Revue de l'ACOMEN, 1, 34 Bury, 1999, Intérêt de la tomographie par émission de positrons (TEP) au 18-fluorodeoxyglucose (18FDG) dans le suivi thérapeutique du cancer pulmonaire non petites cellules (CPNPC), Rev Mal Respir, 16, 46 Coleman, 1999, PET in lung cancer, JNM, 4, 814 Dwamena, 1999, Metastases from non-small cell lung cancer : mediastinal staging in the 1990's : meta-analytic comparison of PET and CT, Radiology, 21, 530, 10.1148/radiology.213.2.r99nv46530 Eary, 1999, Nuclear medicine in cancer diagnosis, Lancet, 354, 853, 10.1016/S0140-6736(99)80041-5 Erasmus, 1999, Positron emission tomography imaging in the thorax, Clin Chest M, 2, 715, 10.1016/S0272-5231(05)70250-1 Frank, 1995, Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings, Int J Radiat Oncol Biol Phys, 3, 1495, 10.1016/0360-3016(94)00622-R Gambhir, 2001, A tabuled summary of the FDG PET literature, J Nucl M, 4, 1 Gould, 1998, Positon emission tomography for mediastinal staging in non small cell lung cancer : a meta-analysis, Am J Respir Crit Care M, 15, 256 Hebert, 1996, Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy : preliminary findings, Am J Clin Oncol, 1, 416, 10.1097/00000421-199608000-00020 Ichiya, 1996, A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma, Ann Nucl M, 1, 193, 10.1007/BF03165392 Kiffer, 1998, The contribution of 18F-fluoro-2-désoxyglucose positron emission tomographic imaging to radiotherapy planning in lung cancer, Lung Cancer, 1, 167, 10.1016/S0169-5002(97)00086-X Koh, 1993, Imaging of hypoxia in humans tumors with 〚F-18〛 fluoromisonidazole, Int J Radiat Oncol Phys, 22, 199, 10.1016/0360-3016(92)91001-4 Landoni, 1999, Comparison of dual-head coincidence imaging PET versus conventional ring PET in tumors patients, Eur J Nucl M, 25, 379 Munley, 1999, Multimodality nuclear medicine imging in three-dimensional radiation treatment planning for lung cancer : challenge and prospects, Lung Cancer, 2, 105, 10.1016/S0169-5002(99)00005-7 Nestle, 1999, Motaref B, et al. 18F-désoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer : high impact in patients with atelectasis, Int J Radiat Oncol Biol Phys, 4, 593, 10.1016/S0360-3016(99)00061-9 Rigo, 1995, Indications cliniques de la tomographie par émission de positons au localisation=« PRE » localisation=« PRE »18FDG en oncologie. Expérience préliminaire et revue de la littérature, Med Nucl IFM, 19, 73 Strauss, 1991, The applications of PET in clinical oncology, J Nucl M, 32, 623 Vansteenkiste, 2001, The role of positon emission tomography with 18F-fluoro-2-Deoxy-D-Glucose in respiratory oncology, Eur Respir J, 17, 802, 10.1183/09031936.01.17408020 Vaylet, 1998, Fluoro-deoxy-glucose et cancer bronchopulmonaire. Les premiers résultats français en caméra à positons, Rev Pneumol Clin, 54, 187 Vuillez, 1998, Métabolisme glucidique des cellules tumorales : conséquences pour l'utilisation de radiopharmaceutiques analogues du glucose, Med Nucl IFM, 22, 9 Wahl, 1993, Metabolic monitoring of breast cancer chemohormontherapy using positron emission tomography. Initial evaluation, J Clin Oncol, 11, 2101, 10.1200/JCO.1993.11.11.2101 Warburg, 1930, On the metabolism of the tumors in the body, 254 Weber, 1999, Imaging of lung cancer with fluorine - 18 fluorodeoxyglucose : comparison of a dual-head camera in coincidence mode with a full-ring positon emission tomography system, Eur J Nucl M, 26, 388, 10.1007/s002590050402